ClinicalTrials.Veeva

Find clinical trials for Chronic Lymphocytic Leukemia in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near Birmingham, AL, USA:

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic...

Enrolling
Chronic Lymphocytic Leukemia
Drug: Loncastuximab Tesirine and Acalabrutinib

Phase 1

Mayur Narkhede

Birmingham, Alabama, United States

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...

Active, not recruiting
Lymphoma, Small Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Biological: JCAR017 (lisocabtagene maraleucel)
Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax

Phase 1, Phase 2

Juno Therapeutics

Birmingham, Alabama, United States and 66 other locations

study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lympho...

Enrolling
Small Lymphocytic Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia
Drug: Venetoclax
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

Birmingham, Alabama, United States and 67 other locations

The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely co...

Active, not recruiting
Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma
Drug: tafasitamab
Drug: parsaclisib

Phase 1, Phase 2

Incyte
Incyte

Birmingham, Alabama, United States and 49 other locations

with relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to furthe...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin
Drug: JNJ-75348780

Phase 1

Janssen
Janssen

Birmingham, Alabama, United States and 31 other locations

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic...

Enrolling
Precursor B-Cell Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Drug: Bendamustine
Drug: Fludarabine

Phase 1

Fate Therapeutics
Fate Therapeutics

Birmingham, Alabama, United States and 14 other locations

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: BGB-16673

Phase 1, Phase 2

BeiGene
BeiGene

Birmingham, Alabama, United States and 57 other locations

evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic...

Enrolling
LGLL - Large Granular Lymphocytic Leukemia
Aggressive NK Cell Leukemia
Drug: DR-01

Phase 1, Phase 2

Dren Bio

Birmingham, Alabama, United States and 19 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems